كليكسان إسرائيل - العربية - Ministry of Health

كليكسان

sanofi - aventis israel ltd - enoxaparin sodium 20 mg / 0.2 ml - solution for injection - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

أبيترن ٥٠ إسرائيل - العربية - Ministry of Health

أبيترن ٥٠

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

ريزدرونات تيڤع ٣٥ ملغ إسرائيل - العربية - Ministry of Health

ريزدرونات تيڤع ٣٥ ملغ

abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

أكتونيل مرة في الشهر ١٥٠ ملغ إسرائيل - العربية - Ministry of Health

أكتونيل مرة في الشهر ١٥٠ ملغ

sanofi - aventis israel ltd - risedronic acid as sodium 150 mg - film coated tablets - risedronic acid - treatment of postmenopausal osteoporosis.prevention of postmenopausal osteoporosis.

أبيترن ١٠٠ إسرائيل - العربية - Ministry of Health

أبيترن ١٠٠

abic ltd. - diclofenac sodium 100 mg - tablets sustained release - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other minor surgery.

أليندرونات تيڤع ٧٠ ملغ إسرائيل - العربية - Ministry of Health

أليندرونات تيڤع ٧٠ ملغ

teva pharmaceutical indust.ltd - alendronic acid as sodium 70 mg - tablets - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.

مونتيلوكاست تيڤع ۱٠ ملغ إسرائيل - العربية - Ministry of Health

مونتيلوكاست تيڤع ۱٠ ملغ

teva pharmaceutical indust.ltd - montelukast as sodium 10 mg - tablets - montelukast - montelukast teva is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast teva is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast teva and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast teva is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.